CY1111708T1 - Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης - Google Patents
Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτηςInfo
- Publication number
- CY1111708T1 CY1111708T1 CY20111100692T CY111100692T CY1111708T1 CY 1111708 T1 CY1111708 T1 CY 1111708T1 CY 20111100692 T CY20111100692 T CY 20111100692T CY 111100692 T CY111100692 T CY 111100692T CY 1111708 T1 CY1111708 T1 CY 1111708T1
- Authority
- CY
- Cyprus
- Prior art keywords
- salt
- composition
- active substance
- acid
- hydroxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 abstract 5
- 239000013543 active substance Substances 0.000 abstract 3
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 abstract 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Παρέχεται σύνθεση ελεγχόμενης απελευθέρωσης περιέχουσα φυσιολογικώς δραστική ουσία σε υψηλή περιεκτικότητα καταστέλλουσα την αρχική υπερβολική απελευθέρωση και επιτυγχάνουσα μία σταθερή ταχύτητα απελευθέρωσης σε μακρά χρονική περίοδο. Μία σύνθεση ελεγχόμενης απελευθέρωσης περιλαμβάνουσα (1) φαρμακολογικώς δραστική ουσία ή άλας αυτής σε μία ποσότητα περίπου 14% (β./β.) έως περίπου 24% (β./β.) επί τη βάσει του συνολικού βάρους της σύνθεσης, (2) υδροξυναφθοϊκό οξύ που επιλέγεται από 3-υδροξυ-2-ναφθοϊκό οξύ και 1 -υδροξυ-2-ναφθοϊκό οξύ ή άλας αυτών και (3) πολυμερές γαλακτικού οξέος ή άλας αυτού που έχει βάρος μέσου μοριακού βάρους 15.000 έως 50.000, όπου η περιεκτικότητα πολυμερών που έχουν μοριακά βάρη 5.000 ή μικρότερο, είναι περίπου 5% κατά βάρος ή μικρότερο, όπου η γραμμομοριακή αναλογία του αναφερθέντος υδροξυναφθοϊκού οξέος ή άλατος αυτού προς την αναφερθείσα φυσιολογικώς δραστική ουσία ή άλας αυτής είναι από 3:4 έως 4:3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001199484 | 2001-06-29 | ||
| JP2001340993 | 2001-11-06 | ||
| EP08003261A EP1949936B1 (en) | 2001-06-29 | 2002-06-28 | Controlled release composition and method of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111708T1 true CY1111708T1 (el) | 2015-10-07 |
Family
ID=26617910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100943T CY1105071T1 (el) | 2001-06-29 | 2006-07-07 | Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης |
| CY20111100692T CY1111708T1 (el) | 2001-06-29 | 2011-07-15 | Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061100943T CY1105071T1 (el) | 2001-06-29 | 2006-07-07 | Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US7429559B2 (el) |
| EP (3) | EP1330293B2 (el) |
| JP (5) | JP2003206240A (el) |
| KR (2) | KR100961413B1 (el) |
| CN (3) | CN1292796C (el) |
| AR (2) | AR034641A1 (el) |
| AT (3) | ATE509668T1 (el) |
| AU (2) | AU2002311631B2 (el) |
| BR (1) | BRPI0210561B8 (el) |
| CA (1) | CA2455392C (el) |
| CO (1) | CO5540367A2 (el) |
| CR (1) | CR11283A (el) |
| CY (2) | CY1105071T1 (el) |
| CZ (1) | CZ306327B6 (el) |
| DE (2) | DE60225481T2 (el) |
| DK (2) | DK1330293T4 (el) |
| ES (2) | ES2366677T3 (el) |
| HU (1) | HU230351B1 (el) |
| IL (3) | IL159059A0 (el) |
| MX (1) | MXPA03011456A (el) |
| MY (1) | MY142066A (el) |
| NO (1) | NO331883B1 (el) |
| NZ (2) | NZ541884A (el) |
| PE (1) | PE20030066A1 (el) |
| PL (1) | PL204903B1 (el) |
| PT (2) | PT1949936E (el) |
| RU (1) | RU2301661C2 (el) |
| SG (1) | SG180015A1 (el) |
| SI (1) | SI1949936T1 (el) |
| SK (1) | SK287577B6 (el) |
| TW (2) | TW200526267A (el) |
| WO (1) | WO2003002092A2 (el) |
| ZA (1) | ZA200309152B (el) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU758596B2 (en) | 1998-01-16 | 2003-03-27 | Takeda Pharmaceutical Company Limited | Sustained release compositions, process for producing the same and utilization thereof |
| TWI225416B (en) * | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
| TW200526267A (en) * | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
| PT1532985T (pt) * | 2002-06-25 | 2017-01-20 | Takeda Pharmaceuticals Co | Processo de produção de uma composição de libertação sustentada |
| CN102166192B (zh) | 2003-04-10 | 2013-09-25 | Pr药品有限公司 | 一种用于生产基于乳化的微观粒子的方法 |
| US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| CA2532302C (en) * | 2003-07-15 | 2016-12-20 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| JP5165240B2 (ja) * | 2003-07-23 | 2013-03-21 | ピーアール ファーマシューティカルズ， インコーポレイテッド | 徐放組成物 |
| TW200529890A (en) | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
| TW200613012A (en) * | 2004-07-02 | 2006-05-01 | Takeda Pharmaceuticals Co | Sustained-release composition, process for producing the same and use of the same |
| US20060251581A1 (en) * | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
| WO2007070563A2 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Stable solid forms of enterostatin |
| RU2427383C2 (ru) | 2006-01-18 | 2011-08-27 | КьюПиЭс, ЭлЭлСи | Фармацевтические композиции с повышенной стабильностью |
| US7858663B1 (en) * | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
| NO347209B1 (no) | 2006-12-18 | 2023-07-03 | Takeda Pharmaceutical | Sammensetning med forlenget frigjøring og fremgangsmåte for å produsere det samme |
| US20110319987A1 (en) * | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
| KR101811797B1 (ko) * | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
| CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法 |
| CN103751851A (zh) * | 2014-01-17 | 2014-04-30 | 东华大学 | 一种无机/有机多药物控释复合纳米纤维支架的制备方法 |
| KR101558083B1 (ko) * | 2014-04-07 | 2015-10-07 | 에스케이케미칼주식회사 | 약물함유 고분자미립구 제조방법 |
| US9956164B2 (en) | 2014-04-16 | 2018-05-01 | Veyx-Pharma Gmbh | Veterinary pharmaceutical composition and use thereof |
| US10787920B2 (en) | 2016-10-12 | 2020-09-29 | General Electric Company | Turbine engine inducer assembly |
| KR102089737B1 (ko) * | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
| WO2024095158A1 (en) | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2025229492A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Orexin type 2 receptor agonist microcapsules for sustained release dosing |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3297033A (en) * | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
| US3565869A (en) * | 1968-12-23 | 1971-02-23 | American Cyanamid Co | Extrudable and stretchable polyglycolic acid and process for preparing same |
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3755558A (en) * | 1971-02-23 | 1973-08-28 | Du Pont | Polylactide drug mixtures for topical application atelet aggregation |
| US3839297A (en) * | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
| US3912692A (en) * | 1973-05-03 | 1975-10-14 | American Cyanamid Co | Process for polymerizing a substantially pure glycolide composition |
| US3890283A (en) * | 1973-06-04 | 1975-06-17 | American Cyanamid Co | Process for post-polymerizing polyglycolic acid |
| US4258063A (en) | 1978-06-23 | 1981-03-24 | Henkel Corporation | Self-emulsifying cosmetic base |
| US4249531A (en) * | 1979-07-05 | 1981-02-10 | Alza Corporation | Bioerodible system for delivering drug manufactured from poly(carboxylic acid) |
| US4273920A (en) * | 1979-09-12 | 1981-06-16 | Eli Lilly And Company | Polymerization process and product |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4479911A (en) * | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
| US4605730A (en) * | 1982-10-01 | 1986-08-12 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
| US4539981A (en) * | 1982-11-08 | 1985-09-10 | Johnson & Johnson Products, Inc. | Absorbable bone fixation device |
| FR2537980B1 (fr) * | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| JPH0678425B2 (ja) | 1984-07-06 | 1994-10-05 | 和光純薬工業株式会社 | 重合体の新規製造法 |
| CA1236641A (en) * | 1984-07-06 | 1988-05-10 | Motoaki Tanaka | Copolymer of lactic acid and glycolic acid and method for producing same |
| ATE61935T1 (de) | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
| JP2551756B2 (ja) † | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| ATE168391T1 (de) * | 1990-04-13 | 1998-08-15 | Takeda Chemical Industries Ltd | Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| US5353086A (en) * | 1993-05-03 | 1994-10-04 | Eastman Kodak Company | Textured surface with canted channels for an automatic tray processor |
| DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
| US5594091A (en) * | 1994-02-21 | 1997-01-14 | Takeda Chemical Industries, Ltd. | Matrix for sustained-release preparation |
| JP3490171B2 (ja) | 1994-02-21 | 2004-01-26 | 武田薬品工業株式会社 | 生体内分解性ポリマーの末端カルボキシル基におけるエステル |
| US5763513A (en) * | 1994-05-19 | 1998-06-09 | Mitsui Toatsu Chemicals, Inc. | L-lactic acid polymer composition, molded product and film |
| JPH08259460A (ja) * | 1995-01-23 | 1996-10-08 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
| JP3902272B2 (ja) * | 1995-09-04 | 2007-04-04 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
| US5922662A (en) * | 1996-08-07 | 1999-07-13 | Colgate Palmolive Company | High foaming nonionic surfactant based liquid detergent |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| AU5678398A (en) | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| JPH10273447A (ja) * | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
| AU758596B2 (en) * | 1998-01-16 | 2003-03-27 | Takeda Pharmaceutical Company Limited | Sustained release compositions, process for producing the same and utilization thereof |
| JPH11269094A (ja) | 1998-01-16 | 1999-10-05 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
| US6114495A (en) * | 1998-04-01 | 2000-09-05 | Cargill Incorporated | Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6756472B1 (en) * | 1998-12-15 | 2004-06-29 | Takeda Chemical Industries, Ltd. | Process for producing polymer |
| JP2000238051A (ja) † | 1999-02-23 | 2000-09-05 | Kansei Corp | 表皮シートの発泡成形型へのセッティング方法 |
| JP2001081043A (ja) * | 1999-07-15 | 2001-03-27 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
| RU2002103718A (ru) | 1999-07-15 | 2003-10-10 | Такеда Кемикал Индастриз, Лтд. (JP) | Композиции пролонгированного действия, способы их получения и применение |
| JP3837607B2 (ja) † | 2000-05-29 | 2006-10-25 | Ｔｃｍ株式会社 | マスト用溶接位置決め治具 |
| EP1693054B1 (en) | 2000-08-07 | 2016-05-25 | Wako Pure Chemical Industries, Ltd. | Lactic acid polymer and process for producing the same |
| AU2002218494A1 (en) * | 2000-11-29 | 2002-06-11 | Takeda Chemical Industries Ltd. | Medicinal compositions and process for producing the same |
| AU2002221139A1 (en) * | 2000-12-15 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
| TW200526267A (en) * | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
-
2002
- 2002-06-26 TW TW094113186A patent/TW200526267A/zh unknown
- 2002-06-26 AR ARP020102406A patent/AR034641A1/es not_active Application Discontinuation
- 2002-06-26 TW TW091114000A patent/TWI332407B/zh not_active IP Right Cessation
- 2002-06-27 PE PE2002000578A patent/PE20030066A1/es active IP Right Grant
- 2002-06-28 BR BR0210561-6 patent/BRPI0210561B8/pt not_active IP Right Cessation
- 2002-06-28 AU AU2002311631A patent/AU2002311631B2/en not_active Expired
- 2002-06-28 CA CA2455392A patent/CA2455392C/en not_active Expired - Fee Related
- 2002-06-28 ES ES08003261T patent/ES2366677T3/es not_active Expired - Lifetime
- 2002-06-28 RU RU2004102507/15A patent/RU2301661C2/ru active
- 2002-06-28 DK DK02738838.8T patent/DK1330293T4/da active
- 2002-06-28 NZ NZ541884A patent/NZ541884A/en not_active IP Right Cessation
- 2002-06-28 EP EP02738838A patent/EP1330293B2/en not_active Expired - Lifetime
- 2002-06-28 EP EP04076939A patent/EP1491236B1/en not_active Expired - Lifetime
- 2002-06-28 SK SK1560-2003A patent/SK287577B6/sk unknown
- 2002-06-28 IL IL15905902A patent/IL159059A0/xx unknown
- 2002-06-28 NZ NZ529969A patent/NZ529969A/en not_active IP Right Cessation
- 2002-06-28 CN CNB028130618A patent/CN1292796C/zh not_active Expired - Lifetime
- 2002-06-28 EP EP08003261A patent/EP1949936B1/en not_active Expired - Lifetime
- 2002-06-28 DE DE60225481T patent/DE60225481T2/de not_active Expired - Lifetime
- 2002-06-28 DK DK08003261.8T patent/DK1949936T3/da active
- 2002-06-28 DE DE60211464T patent/DE60211464T3/de not_active Expired - Lifetime
- 2002-06-28 PT PT08003261T patent/PT1949936E/pt unknown
- 2002-06-28 PT PT02738838T patent/PT1330293E/pt unknown
- 2002-06-28 SI SI200230949T patent/SI1949936T1/sl unknown
- 2002-06-28 ES ES02738838T patent/ES2263788T5/es not_active Expired - Lifetime
- 2002-06-28 MY MYPI20022474A patent/MY142066A/en unknown
- 2002-06-28 WO PCT/JP2002/006527 patent/WO2003002092A2/en not_active Ceased
- 2002-06-28 JP JP2002189247A patent/JP2003206240A/ja active Pending
- 2002-06-28 HU HU0400378A patent/HU230351B1/hu unknown
- 2002-06-28 AT AT08003261T patent/ATE509668T1/de active
- 2002-06-28 US US10/182,731 patent/US7429559B2/en not_active Expired - Fee Related
- 2002-06-28 KR KR1020097001485A patent/KR100961413B1/ko not_active Expired - Fee Related
- 2002-06-28 MX MXPA03011456A patent/MXPA03011456A/es active IP Right Grant
- 2002-06-28 KR KR1020037017129A patent/KR100916173B1/ko not_active Expired - Lifetime
- 2002-06-28 AT AT04076939T patent/ATE387937T1/de not_active IP Right Cessation
- 2002-06-28 SG SG2005085675A patent/SG180015A1/en unknown
- 2002-06-28 AT AT02738838T patent/ATE326264T1/de active
- 2002-06-28 CZ CZ2003-3493A patent/CZ306327B6/cs not_active IP Right Cessation
- 2002-06-28 PL PL367518A patent/PL204903B1/pl unknown
- 2002-06-28 CN CNB2005100896706A patent/CN100348265C/zh not_active Expired - Fee Related
- 2002-06-28 CN CN200610093268A patent/CN100577206C/zh not_active Expired - Fee Related
-
2003
- 2003-11-25 IL IL159059A patent/IL159059A/en active IP Right Grant
- 2003-11-25 ZA ZA2003/09152A patent/ZA200309152B/en unknown
- 2003-12-19 NO NO20035738A patent/NO331883B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111729A patent/CO5540367A2/es active IP Right Grant
-
2004
- 2004-04-13 JP JP2004117981A patent/JP2004238400A/ja not_active Withdrawn
-
2006
- 2006-07-07 CY CY20061100943T patent/CY1105071T1/el unknown
- 2006-12-01 AU AU2006246508A patent/AU2006246508B2/en not_active Ceased
-
2007
- 2007-10-18 IL IL186782A patent/IL186782A0/en unknown
-
2008
- 2008-07-29 US US12/181,472 patent/US8067030B2/en not_active Expired - Fee Related
-
2009
- 2009-03-18 JP JP2009065612A patent/JP2009167203A/ja not_active Withdrawn
-
2010
- 2010-02-18 CR CR11283A patent/CR11283A/es unknown
- 2010-04-26 JP JP2010101265A patent/JP4819173B2/ja not_active Expired - Lifetime
- 2010-04-26 JP JP2010101264A patent/JP4819172B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-16 US US13/064,282 patent/US8246987B2/en not_active Expired - Fee Related
- 2011-07-15 CY CY20111100692T patent/CY1111708T1/el unknown
-
2012
- 2012-07-13 US US13/548,463 patent/US8815801B2/en not_active Expired - Lifetime
-
2014
- 2014-11-03 AR ARP140104096A patent/AR098261A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111708T1 (el) | Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης | |
| CY1117889T1 (el) | Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου | |
| ATE272394T1 (de) | Zubereitung mit verzögerter freisetzung | |
| CO5570652A2 (es) | Productos en gel para la axila, con componente de bloqueo de agua | |
| MXPA05012791A (es) | Formulacion sostenida que contiene dimeticona. | |
| MXPA03011440A (es) | Composicion de liberacion sostenida y proceso para producirla. | |
| CY1105559T1 (el) | Φαρμακευτικες συνθεσεις του tegaserod | |
| EP1197208A4 (en) | COMPOSITIONS WITH DELAYED RELEASE, METHOD FOR THEIR PRODUCTION AND USE | |
| EA200000584A2 (ru) | Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием | |
| SE0300010D0 (sv) | Novel Compounds | |
| AR031399A1 (es) | Un compuesto cosmetico en emulsion clara, antitranspirante y/o desodorante | |
| ATE371680T1 (de) | Polymerkonjugate | |
| CY1105608T1 (el) | Φαρμακευτικες συνθεσεις παραγωγου του λευκοχρυσου | |
| BR0212052A (pt) | Preparação de composição farmacêutica de liberação prolongada | |
| ATE197808T1 (de) | In wässriger lösung redispergierbare polymerpulver | |
| MXPA04003076A (es) | Productos para debajo del brazo con un componente de fijacion de agua. | |
| JP2002525323A5 (el) | ||
| JPH1072323A (ja) | 毛髪化粧料 | |
| DE502005010427D1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
| TW200500452A (en) | Process for preparing a flame retardant polyamide compound | |
| EP1236744A3 (en) | Guanidin-group containing polymer, cosmetic employing same and method of preparing same | |
| CA2529441A1 (en) | Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas | |
| ATE437664T1 (de) | Resorbierbare biokompatible beschichtungen | |
| ATE374044T1 (de) | Wirkstoffhaltige polymerteilchen | |
| SE0103528D0 (sv) | Topiska kompositioner med förstärkt effekt |